Ana María Martín Suárez-rekin lankidetzan egindako argitalpenak (18)

2024

  1. Discrepancies in Electronic Medical Prescriptions Found in a Hospital Emergency Department: A Prospective Observational Study

    Pharmaceuticals, Vol. 17, Núm. 4

2023

  1. Efectos adversos de la interacción triple whammy detectados en un servicio de urgencias hospitalario

    Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias, Vol. 35, Núm. 5, pp. 394-396

  2. Medication delivery errors in outpatients with percutaneous endoscopic gastrostomy: effect on tube feeding replacement

    Scientific Reports, Vol. 13, Núm. 1

2022

  1. Physiologically-based pharmacokinetic modelling and dosing evaluation of gentamicin in neonates using PhysPK

    Frontiers in Pharmacology, Vol. 13

2021

  1. Evaluation of current amikacin dosing recommendations and development of an interactive nomogram: The role of albumin

    Pharmaceutics, Vol. 13, Núm. 2, pp. 1-13

2020

  1. A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease

    British Journal of Clinical Pharmacology, Vol. 86, Núm. 6, pp. 1165-1175

  2. Amikacin initial dosage in patients with hypoalbuminaemia: an interactive tool based on a population pharmacokinetic approach

    The Journal of antimicrobial chemotherapy, Vol. 75, Núm. 8, pp. 2222-2231

2019

  1. Evaluation of renal function equations to predict amikacin clearance

    Expert Review of Clinical Pharmacology, Vol. 12, Núm. 8, pp. 805-813

  2. Therapeutic drug monitoring of tumour necrosis factor inhibitors in the management of chronic inflammatory diseases

    Annals of Clinical Biochemistry, Vol. 56, Núm. 1, pp. 28-41

2018

  1. Diseño y validación de una ecuación para la dosificación inicial de vancomicina en pacientes ancianos

    Farmajournal, Vol. 3, Núm. 1, pp. 111-119

2017

  1. Pharmacokinetics and dosing requirements of digoxin in pregnant women treated for fetal supraventricular tachycardia

    Expert Review of Clinical Pharmacology, Vol. 10, Núm. 8, pp. 911-917

2011

  1. Modification of the EMIT immunoassay for the measurement of unbound mycophenolic acid in plasma

    Clinical Biochemistry, Vol. 44, Núm. 2-3, pp. 260-263

2010

  1. Clinical repercussions of analytical interferences due to aldosterone antagonists in digoxin immunoassays: An assessment

    Therapeutic Drug Monitoring, Vol. 32, Núm. 2, pp. 169-176

2004

  1. Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates

    Journal of Antimicrobial Chemotherapy, Vol. 54, Núm. 1, pp. 193-198

1997

  1. Minimizing digoxin-like immunoreactivity with TDx digoxin in dialysis patients [1]

    Therapeutic Drug Monitoring

1993

  1. Digoxin pharmacokinetics in patients with high serum digoxin concentrations

    Journal of Clinical Pharmacy and Therapeutics, Vol. 18, Núm. 1, pp. 63-68

1989

  1. Interaction between digoxin and propafenone

    Therapeutic Drug Monitoring, Vol. 11, Núm. 1, pp. 10-15

1987

  1. Interacción digoxina-propafenona.

    Medicina Clinica